Get the Stockscreener App
11.21
0.36%
+0.04
Dynavax Technologies Corp. stock is currently priced at $11.21, with a 24-hour trading volume of 1.59M.
It has seen a +0.36% increased in the last 24 hours and a -9.38% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $11.23 pivot point. If it approaches the $11.04 support level, significant changes may occur.
Previous Close:
$11.17
Open:
$11.11
24h Volume:
1.59M
Market Cap:
$1.47B
Revenue:
$232.28M
Net Income/Loss:
$-6.39M
P/E Ratio:
28.74
EPS:
0.39
Net Cash Flow:
$96.46M
1W Performance:
-5.00%
1M Performance:
-9.38%
6M Performance:
-21.66%
1Y Performance:
+6.26%
1D Range:
$11.03
$11.26
52W Range:
$10.06
$15.15
Dynavax Technologies Corp. Stock (DVAX) Company Profile
Name
Dynavax Technologies Corp.
Sector
Phone
510-848-5100
Address
2929 Seventh Street, Suite 100, Berkeley, CA
Dynavax Technologies Corp. Stock (DVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-01-24 | Initiated | Goldman | Neutral |
| Sep-27-22 | Initiated | JMP Securities | Mkt Outperform |
| Jan-06-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Initiated | Goldman | Buy |
| Aug-07-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-20 | Initiated | Evercore ISI | Outperform |
| Oct-18-19 | Initiated | H.C. Wainwright | Buy |
| Jul-11-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-27-19 | Reiterated | Cantor Fitzgerald | Overweight |
| May-10-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-25-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-31-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-31-17 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-09-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Apr-28-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-27-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Initiated | RBC Capital Mkts | Outperform |
| Nov-25-13 | Upgrade | MLV & Co | Hold → Buy |
| Feb-25-13 | Downgrade | MLV & Co | Buy → Hold |
| Nov-16-12 | Reiterated | MLV & Co | Buy |
View All
Dynavax Technologies Corp. Stock (DVAX) Latest News
Dynavax Technologies (DVAX) Q4 2023 Earnings Call Transcript
The Motley Fool
Dynavax Technologies (DVAX) Reports Break-Even Earnings for Q4
Zacks Investment Research
Why Vera Therapeutics Stock Soared by 22% This Week
The Motley Fool
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks
MarketWatch
Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong
Zacks Investment Research
Dynavax Technologies Corp. Stock (DVAX) Financials Data
Dynavax Technologies Corp. (DVAX) Revenue 2024
DVAX reported a revenue (TTM) of $232.28 million for the quarter ending December 31, 2023, a -67.86% decline year-over-year.
Dynavax Technologies Corp. (DVAX) Net Income 2024
DVAX net income (TTM) was -$6.39 million for the quarter ending December 31, 2023, a -102.18% decrease year-over-year.
Dynavax Technologies Corp. (DVAX) Cash Flow 2024
DVAX recorded a free cash flow (TTM) of $96.46 million for the quarter ending December 31, 2023, a +73.56% increase year-over-year.
Dynavax Technologies Corp. (DVAX) Earnings per Share 2024
DVAX earnings per share (TTM) was -$0.06 for the quarter ending December 31, 2023, a -103.05% decline year-over-year.
Dynavax Technologies Corp. Stock (DVAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Burgess Justin | Chief Accounting Officer |
Mar 01 '24 |
Sale |
12.78 |
20,526 |
262,322 |
0 |
| Janssen Robert | SVP and CMO |
Jan 04 '24 |
Option Exercise |
9.41 |
1,500 |
14,115 |
51,425 |
| Janssen Robert | SVP and CMO |
Jan 04 '24 |
Sale |
15.00 |
1,500 |
22,500 |
49,925 |
| Novack David F | President & COO |
Jan 02 '24 |
Option Exercise |
5.42 |
9,000 |
48,780 |
12,187 |
| Novack David F | President & COO |
Jan 02 '24 |
Sale |
14.45 |
9,000 |
130,050 |
3,187 |
| Novack David F | President & COO |
Dec 01 '23 |
Option Exercise |
5.42 |
20,000 |
108,400 |
23,187 |
| Novack David F | President & COO |
Dec 01 '23 |
Sale |
13.56 |
20,000 |
271,200 |
3,187 |
| Novack David F | President & COO |
Nov 03 '23 |
Option Exercise |
5.42 |
20,000 |
108,400 |
23,187 |
| Novack David F | President & COO |
Nov 03 '23 |
Sale |
15.00 |
20,000 |
300,000 |
3,187 |
| Novack David F | President & COO |
Nov 01 '23 |
Option Exercise |
5.42 |
20,000 |
108,400 |
23,187 |
About Dynavax Technologies Corp.
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for oncology. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.
1.69%
1.28%
Cap:
|
Volume (24h):